AIMS: Cardiac fibrosis is associated with increased incidence of cardiac arrhythmias, but the underlying proarrhythmic mechanisms remain incompletely understood and antiarrhythmic therapies are still suboptimal. This study tests the hypothesis that myofibroblast (MFB) proliferation leads to tachyarrhythmias by altering the excitability of cardiomyocytes (CMCs) and that inhibition of MFB proliferation would thus lower the incidence of such arrhythmias. METHODS AND RESULTS: Endogenous MFBs in neonatal rat CMC cultures proliferated freely or under control of different dosages of antiproliferative agents (mitomycin-C and paclitaxel). At Days 4 and 9, arrhythmogeneity of these cultures was studied by optical and multi-electrode mapping. Cultures were also studied for protein expression and electrophysiological properties. MFB proliferation slowed conduction from 15.3 ± 3.5 cm/s (Day 4) to 8.8 ± 0.3 cm/s (Day 9) (n = 75, P < 0.01), whereas MFB numbers increased to 37.4 ± 1.7 and 62.0 ± 2%. At Day 9, 81.3% of these cultures showed sustained spontaneous reentrant arrhythmias. However, only 2.6% of mitomycin-C-treated cultures (n = 76, P < 0.0001) showed tachyarrhythmias, and ectopic activity was decreased. Arrhythmia incidence was drug-dose dependent and strongly related to MFB proliferation. Paclitaxel treatment yielded similar results. CMCs were functionally coupled to MFBs and more depolarized in cultures with ongoing MFB proliferation in which only L-type Ca(2+)-channel blockade terminated 100% of reentrant arrhythmias, in contrast to Na(+) blockade (36%, n = 12). CONCLUSION: Proliferation of MFBs in myocardial cultures gives rise to spontaneous, sustained reentrant tachyarrhythmias. Antiproliferative treatment of such cultures prevents the occurrence of arrhythmias by limiting MFB-induced depolarization, conduction slowing, and ectopic activity. This study could provide a rationale for a new treatment option for cardiac arrhythmias.
AIMS: Cardiac fibrosis is associated with increased incidence of cardiac arrhythmias, but the underlying proarrhythmic mechanisms remain incompletely understood and antiarrhythmic therapies are still suboptimal. This study tests the hypothesis that myofibroblast (MFB) proliferation leads to tachyarrhythmias by altering the excitability of cardiomyocytes (CMCs) and that inhibition of MFB proliferation would thus lower the incidence of such arrhythmias. METHODS AND RESULTS: Endogenous MFBs in neonatal rat CMC cultures proliferated freely or under control of different dosages of antiproliferative agents (mitomycin-C and paclitaxel). At Days 4 and 9, arrhythmogeneity of these cultures was studied by optical and multi-electrode mapping. Cultures were also studied for protein expression and electrophysiological properties. MFB proliferation slowed conduction from 15.3 ± 3.5 cm/s (Day 4) to 8.8 ± 0.3 cm/s (Day 9) (n = 75, P < 0.01), whereas MFB numbers increased to 37.4 ± 1.7 and 62.0 ± 2%. At Day 9, 81.3% of these cultures showed sustained spontaneous reentrant arrhythmias. However, only 2.6% of mitomycin-C-treated cultures (n = 76, P < 0.0001) showed tachyarrhythmias, and ectopic activity was decreased. Arrhythmia incidence was drug-dose dependent and strongly related to MFB proliferation. Paclitaxel treatment yielded similar results. CMCs were functionally coupled to MFBs and more depolarized in cultures with ongoing MFB proliferation in which only L-type Ca(2+)-channel blockade terminated 100% of reentrant arrhythmias, in contrast to Na(+) blockade (36%, n = 12). CONCLUSION: Proliferation of MFBs in myocardial cultures gives rise to spontaneous, sustained reentrant tachyarrhythmias. Antiproliferative treatment of such cultures prevents the occurrence of arrhythmias by limiting MFB-induced depolarization, conduction slowing, and ectopic activity. This study could provide a rationale for a new treatment option for cardiac arrhythmias.
Authors: Dirk L Ypey; Wilbert P M van Meerwijk; Soban Umar; Daniel A Pijnappels; Martin J Schalij; Arnoud van der Laarse Journal: Eur Biophys J Date: 2012-10-23 Impact factor: 1.733
Authors: Markus Horsthemke; Lauryl M J Nutter; Anne C Bachg; Boris V Skryabin; Ulrike Honnert; Thomas Zobel; Sven Bogdan; Monika Stoll; Matthias D Seidl; Frank U Müller; Ursula Ravens; Andreas Unger; Wolfgang A Linke; Pim R R van Gorp; Antoine A F de Vries; Martin Bähler; Peter J Hanley Journal: J Biol Chem Date: 2019-02-08 Impact factor: 5.157
Authors: Matthew T McPheeters; Yves T Wang; Andreas A Werdich; Michael W Jenkins; Kenneth R Laurita Journal: PLoS One Date: 2017-08-24 Impact factor: 3.240
Authors: Ariane C C van Spreeuwel; Noortje A M Bax; Bastiaan J van Nierop; Annemieke Aartsma-Rus; Marie-José T H Goumans; Carlijn V C Bouten Journal: J Cardiovasc Transl Res Date: 2017-03-09 Impact factor: 4.132
Authors: Geran M Kostecki; Yu Shi; Christopher S Chen; Daniel H Reich; Emilia Entcheva; Leslie Tung Journal: Sci Rep Date: 2021-02-24 Impact factor: 4.379
Authors: A Dénise den Haan; Marieke W Veldkamp; Diane Bakker; Geert J J Boink; Rob B Janssen; Jacques M T de Bakker; Hanno L Tan Journal: PLoS One Date: 2013-03-13 Impact factor: 3.240
Authors: Rupamanjari Majumder; Marc C Engels; Antoine A F de Vries; Alexander V Panfilov; Daniël A Pijnappels Journal: Sci Rep Date: 2016-04-13 Impact factor: 4.379